Core Viewpoint - Zynex, Inc. is facing allegations of issuing materially false and misleading statements regarding its business practices, particularly related to inflated revenue and improper product shipments during the class period from March 13, 2023, to March 11, 2025 [1]. Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [1]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is May 19, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1][3]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants' positive statements regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The lawsuit against Cerevel Therapeutics Holdings, Inc. alleges that the company and its controlling shareholder, Bain Capital, engaged in misleading practices regarding a secondary stock offering and the subsequent acquisition by AbbVie, resulting in significant financial losses for shareholders [2]. Group 1: Allegations and Financial Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a price significantly higher than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger announcement [2]. - Bain Capital acquired shares during the October Offering at a depressed price while allegedly possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2]. - Cerevel's January 18, 2024 Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3].

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=148823&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering and subsequent merger with AbbVie Inc. [1] Group 1: Class Action Details - The class action lawsuit is on behalf of individuals or entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [3] - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost to participate [5] Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4] Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [6]

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements and inflating revenue through improper business practices during the class period from March 13, 2023, to March 11, 2025 [3]. Summary by Relevant Sections Allegations - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [3]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [3]. - As a result of these practices, Zynex is likely to face adverse consequences, including removal from insurer networks and federal penalties [3]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [3]. Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to register for the class action [4]. - The deadline for shareholders to seek lead plaintiff status is May 19, 2025 [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Solaris Energy Infrastructure, Inc. (NYSE: SEI). Shareholders who purchased shares of SEI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/solaris-energy-infrastructure-inc-loss-submission-form/?id=148462&f ...

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Digimarc Corporation (NASDAQ: DMRC).Shareholders who purchased shares of DMRC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/digimarc-corporation-loss-submission-form-2/?id=148443&from=4CLASS PERIOD: May 3, 202 ...

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Open Lending Corporation (NASDAQ: LPRO).Shareholders who purchased shares of LPRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/open-lending-corporation-loss-submission-form/?id=148440&from=4 CLASS PERIOD: Feb ...

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Civitas Resources, Inc. (NYSE: CIVI).Shareholders who purchased shares of CIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/civitas-resources-loss-submission-form/?id=148441&from=4CLASS PERIOD: February 27, 2 ...